<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/Sensei-Bio--430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/Sensei-Bio--430x241.jpg"/></p>
<p>Sensei Biotherapeutics 正在准备结束其主要资产的临床研究，同时考虑出售公司。图片来源：eamesBot/ Shutterstock.com。</p>
<p>Sensei Biotherapeutics 将放弃其唯一的临床阶段资产 solnerstotug，并准备裁减员工，考虑下一步行动。</p>
<p>这一消息在这家免疫肿瘤生物技术公司发布了针对实体肿瘤候选药物的积极 I 期剂量扩展数据并宣布计划进入 II 期测试后仅几周传出。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>免疫肿瘤学 (IO) - 主题情报</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>在一项 I/II 期研究 (NCT05864144) 中，接受 15mg/kg solnerstotug 治疗的抗 PD-L1 耐药患者的六个月无进展生存期 (PFS) 达到 50%。Solnerstotug 是一种单克隆抗体，针对 T 细胞激活的 V 域 Ig 抑制因子 (VISTA)，设计为在低 pH 肿瘤微环境中有条件活跃。该数据在 2025 年 10 月 17-21 日于德国柏林举行的欧洲医学肿瘤学会 (ESMO) 大会上发布。</p>
<p>根据其在 ESMO 会议后的公告，Sensei 原计划在 2026 年启动两项 II 期研究，针对抗 PD-L1 耐药的非小细胞肺癌 (NSCLC) 和梅克尔细胞癌 (MCC)，这取决于 FDA 的反馈和资本筹集。</p>
<p>现在看来，这家生物技术公司已撤回进一步临床测试的计划，并正在探索未来的选项，包括出售其资产、合并、出售公司或结束运营。根据 Sensei 的说法，这一决定来自董事会，经过对公司管道和市场状况的广泛讨论。该生物技术公司还表示，计划裁员以保留现金。</p>
<p>“我们现在的角色是谨慎管理公司及其资产，包括有序结束正在进行的 I/II 期临床试验和保护股东价值，” Sensei 的总裁兼首席执行官 John Celebi 说道。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报的信息</p>
<h2>Sensei 的动荡历史</h2>
<p>去年，Sensei 宣布将裁减 46% 的员工，并关闭位于美国马里兰州罗克维尔的研究中心。这一举措被描述为一次全公司范围的重组，旨在将资源集中于推进 solnerstotug，当时称为 SNS-101，在公司 2024 年第三季度财报发布中提到。</p>
<p>近年来，Sensei 遭遇了多次挫折，包括一系列被放弃的临床和前临床项目。早在 2021 年，这家生物技术公司就停止了 SNS-301 的开发，这是其唯一一个进入临床阶段的资产。SNS-301 是一种首创的纳米颗粒疫苗，针对人类天冬氨酸 β-羟化酶 (ASPH)，并在包括慢性髓系单核细胞白血病 (CMML) 和头颈部鳞状细胞癌 (HNSCC) 在内的多种癌症类型中进行研究。在过去几年中，至少有四项针对 SNS-301 的 I 期或 II 期试验在宣布后被撤回或终止，依据是 GlobalData，<em>Pharmaceutical Technology</em> 的母公司。</p>
<h2>制药技术卓越奖 - 参赛的好处</h2>
<p>获得应有的认可！制药技术卓越奖 庆祝创新、领导力和影响力。通过参赛，您展示了自己的成就，提升了行业形象，并将自己定位于推动制药进步的顶尖领导者之中。不要错过脱颖而出的机会 - 今天就提交您的参赛作品！</p>
<p>立即提名</p>

SNSE

<p>Sensei Biotherapeutics 正在停止其主要临床阶段资产 solnerstotug 的开发，并裁减员工，作为旨在最大化股东价值的战略审查的一部分。尽管第一阶段数据表现积极，公司仍在探索包括出售或合并在内的选项。此决定是在之前裁员和临床管道遭遇挫折之后做出的。首席执行官 John Celebi 强调在这一过渡期间需要保护现金和股东价值</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/Sensei-Bio--430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/10/Sensei-Bio--430x241.jpg"/></p>
<p>Sensei Biotherapeutics is preparing to wind-down clinical investigation of its lead asset, as it considers a company sale. Credit: eamesBot/ Shutterstock.com.</p>
<div class="lb-trans"><p>Sensei Biotherapeutics 正在准备结束其主要资产的临床研究，同时考虑出售公司。图片来源：eamesBot/ Shutterstock.com。</p>
</div><p>Sensei Biotherapeutics is set to abandon its sole clinical-stage asset solnerstotug as it prepares to cut its workforce and consider next steps.</p>
<div class="lb-trans"><p>Sensei Biotherapeutics 将放弃其唯一的临床阶段资产 solnerstotug，并准备裁减员工，考虑下一步行动。</p>
</div><p>This news comes just weeks after the immuno-oncology biotech released positive Phase I dose expansion data for the solid-tumour candidate and announced plans to proceed to Phase II testing.</p>
<div class="lb-trans"><p>这一消息在这家免疫肿瘤生物技术公司发布了针对实体肿瘤候选药物的积极 I 期剂量扩展数据并宣布计划进入 II 期测试后仅几周传出。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Immuno-oncology (IO) - Thematic Intelligence</h4>
<div class="lb-trans"><h4>免疫肿瘤学 (IO) - 主题情报</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>In a Phase I/II study (NCT05864144) with the drug, the six-month progression-free survival (PFS) reached 50% in anti-PD-L1 resistant patients treated with 15mg/kg solnerstotug. Solnerstotug is a monoclonal antibody targeting V-domain Ig suppressor of T-cell activation (VISTA), designed to be conditionally active in a low-pH tumour microenvironment. This data was presented at the European Society for Medical Oncology (ESMO) Congress 2025, held October 17–21 in Berlin, Germany.</p>
<div class="lb-trans"><p>在一项 I/II 期研究 (NCT05864144) 中，接受 15mg/kg solnerstotug 治疗的抗 PD-L1 耐药患者的六个月无进展生存期 (PFS) 达到 50%。Solnerstotug 是一种单克隆抗体，针对 T 细胞激活的 V 域 Ig 抑制因子 (VISTA)，设计为在低 pH 肿瘤微环境中有条件活跃。该数据在 2025 年 10 月 17-21 日于德国柏林举行的欧洲医学肿瘤学会 (ESMO) 大会上发布。</p>
</div><p>Sensei had planned to initiate two Phase II studies in 2026 in patients with anti-PD-L1-resistant non-small cell lung cancer (NSCLC) and merkel cell carcinoma (MCC) subject to FDA feedback and capital fundraising, as per its announcement following the ESMO presentations.</p>
<div class="lb-trans"><p>根据其在 ESMO 会议后的公告，Sensei 原计划在 2026 年启动两项 II 期研究，针对抗 PD-L1 耐药的非小细胞肺癌 (NSCLC) 和梅克尔细胞癌 (MCC)，这取决于 FDA 的反馈和资本筹集。</p>
</div><p>It now emerges that the biotech has withdrawn plans for further clinical testing and is exploring options for the future, including a sale of its assets, a merger, a sale of the company, or a wind-down of operations. The decision comes from the Board of Directors after extensive discussions around the company’s pipeline and market conditions, according to Sensei. The biotech also said it plans to initiate job losses in an effort to preserve cash.</p>
<div class="lb-trans"><p>现在看来，这家生物技术公司已撤回进一步临床测试的计划，并正在探索未来的选项，包括出售其资产、合并、出售公司或结束运营。根据 Sensei 的说法，这一决定来自董事会，经过对公司管道和市场状况的广泛讨论。该生物技术公司还表示，计划裁员以保留现金。</p>
</div><p>“Our role now is to steward the company and its assets with care, including an orderly wind-down of the ongoing Phase I/II clinical trial and preservation of shareholder value,” said John Celebi, president and CEO of Sensei.</p>
<div class="lb-trans"><p>“我们现在的角色是谨慎管理公司及其资产，包括有序结束正在进行的 I/II 期临床试验和保护股东价值，” Sensei 的总裁兼首席执行官 John Celebi 说道。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报的信息</p>
</div><h2>Sensei’s turbulent history</h2>
<div class="lb-trans"><h2>Sensei 的动荡历史</h2>
</div><p>Last year, Sensei had announced it would be slashing 46% percent of its workforce and closing its research site in Rockville, Maryland, US. The move was described as an organisation-wide restructure to focus its resources on advancing solnerstotug, then called SNS-101, in the company’s Q3 earnings press release in November 2024.</p>
<div class="lb-trans"><p>去年，Sensei 宣布将裁减 46% 的员工，并关闭位于美国马里兰州罗克维尔的研究中心。这一举措被描述为一次全公司范围的重组，旨在将资源集中于推进 solnerstotug，当时称为 SNS-101，在公司 2024 年第三季度财报发布中提到。</p>
</div><p>Sensei has suffered multiple setbacks in recent years, including a series of abandoned clinical and preclinical programmes. Back in 2021, the biotech discontinued development of SNS-301, its only other asset to reach clinical-stage investigation. SNS-301 was a first-in-class nanoparticle vaccine targeting human aspartate β-hydroxylase (ASPH) and was being investigated in various cancer types including chronic myelomonocytic leukemia (CMML) and head and neck squamous cell carcinoma (HNSCC). In the last few years, at least four Phase I or II-stage trials investigating SNS-301 were withdrawn or terminated after being announced, as per GlobalData, the parent company of <em>Pharmaceutical Technology</em>.</p>
<div class="lb-trans"><p>近年来，Sensei 遭遇了多次挫折，包括一系列被放弃的临床和前临床项目。早在 2021 年，这家生物技术公司就停止了 SNS-301 的开发，这是其唯一一个进入临床阶段的资产。SNS-301 是一种首创的纳米颗粒疫苗，针对人类天冬氨酸 β-羟化酶 (ASPH)，并在包括慢性髓系单核细胞白血病 (CMML) 和头颈部鳞状细胞癌 (HNSCC) 在内的多种癌症类型中进行研究。在过去几年中，至少有四项针对 SNS-301 的 I 期或 II 期试验在宣布后被撤回或终止，依据是 GlobalData，<em>Pharmaceutical Technology</em> 的母公司。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 参赛的好处</h2>
</div><p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
<div class="lb-trans"><p>获得应有的认可！制药技术卓越奖 庆祝创新、领导力和影响力。通过参赛，您展示了自己的成就，提升了行业形象，并将自己定位于推动制药进步的顶尖领导者之中。不要错过脱颖而出的机会 - 今天就提交您的参赛作品！</p>
</div><p>Nominate Now</p>
<div class="lb-trans"><p>立即提名</p>
</div>

Sensei Biotherapeutics 将在战略评估中放弃其主要候选药物并裁减员工